NEW YORK (GenomeWeb) – Nanopore-based sequencing firm Quantapore today announced it closed a Series B financing round raising up to $35 million.

The Menlo Park, Calif.-based firm did not disclose the name of the investors but said that the funds will go toward finalizing the development of its sequencing technology and commercializing its platform.

The final amount of the raise will depend on whether Quantapore meets certain milestones before all funds are released, Quantapore CEO Martin Huber said in an email.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.